The generic industry's thirst for more ANDA approvals appears to have been overtaken by concerns about the effect (or lack thereof) that those products are having on drug prices.
The US FDA began fiscal year 2019 by punching through the 100-approval-per-month barrier. The 110 full approvals in October is...